---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-107949"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:40:52.271862+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cadrenal Therapeutics Q3 2025 net loss $2.7M; advances tecarfarin and frunexian pipeline

## Summary
- Net loss of $2.7M for Q3 2025 vs $2.4M in Q3 2024; cash and equivalents $3.9M as of Sept 30.
- R&D expense $0.7M (down from $0.8M); G&A expense $2.0M (up from $1.7M) year-over-year.
- Completed cGMP manufacturing of tecarfarin; ongoing Phase 2 LVAD study with Abbott.
- Acquired eXIthera Pharmaceuticals assets in Sept 2025, including frunexian, a Phase 2-ready IV Factor XIa inhibitor.
- ~2.1M common shares outstanding as of Sept 30, 2025.

## SEC filing metadata
- accession: 0001213900-25-107949
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390025107949/0001213900-25-107949-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390025107949/ea0264724-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-107949
- JSON: https://secwatch.observer/filing/0001213900-25-107949.json
- Plain text: https://secwatch.observer/filing/0001213900-25-107949.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.